5 active not recruiting, 5 recruiting, 3 unknown, 2 completed. 5 Phase 2, 4 Phase 3, 3 Phase 1, 1 Not applicable, 1 Phase 4.
Follow Hormone Sensitive Prostate Cancer: new trials by email Literature Review of Hormone Sensitive Prostate Cancer trials Research Report on Hormone Sensitive Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. Mevrometostat, Placebo, Enzalutamide - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer | Phase 3 | Recruiting | Pfizer | 1000 | 2025-09-28 | 2026-10-14 |
| Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) Darolutamide, Relugolix - Prostate Cancer, Advanced Prostate Cancer | Phase 2 | Active not recruiting | Atish Choudhury, MD | 33 | 2024-12-13 | 2026-03-09 |
| PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Miami | 34 | 2024-07-03 | 2026-06-16 |
| PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer 18F-rhPSMA-7.3, PET/CT - Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer | Phase 4 | Active not recruiting | Brigham and Women's Hospital | 20 | 2024-06-30 | 2026-10-29 |
| [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer [Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC) - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Active not recruiting | Eli Lilly and Company | 142 | 2024-04-03 | 2026-10-06 |
| Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC Docetaxel, Rezvilutamide - Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 200 | 2023-08-01 | 2023-08-09 |
| Metastasis-directed Therapy for Oligorecurrent Prostate Cancer Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 873 | 2022-04-20 | 2024-07-03 |
| Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients Abiraterone Acetate - Prostate Cancer, Metastatic Cancer | Phase 1 | Unknown | National University Hospital, Singapore | 10 | 2021-11-30 | 2024-01-08 |
| A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer SHR7280 - Hormone Sensitive Prostate Cancer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2021-09-24 | 2023-09-21 |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide Darolutamide, Enzalutamide - Metastatic Prostate Cancer, Prostate Cancer Metastatic | Phase 2 | Completed | Alliance Foundation Trials, LLC. | 111 | 2021-08-17 | 2026-09-21 |
| Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors Androgen Deprivation Therapy, Nivolumab, Docetaxel - Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Xiao X. Wei, MD | 47 | 2020-05-11 | 2026-08-12 |
| Cardiovascular Events in GnRH Agonist vs. Antagonist Degarelix, GnRH agonist - Hormone Sensitive Prostate Cancer, Prostate Cancer | Phase 2 | Unknown | Rabin Medical Center | 80 | 2020-01-17 | 2019-12-02 |
| Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer Neoadjuvant chemotherapy combined with hormone therapy, Neoadjuvant hormone therapy, Radical Prostatectomy (RP)+ extended lymph node dissection - Prostate Cancer, Chemotherapy Effect | Not applicable | Unknown | RenJi Hospital | 475 | 2020-01-10 | 2020-01-07 |
| Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients Docetaxel, Apalutamide Oral Tablet, Enzalutamide Oral Tablet - Prostate Cancer, Hormone Sensitive Prostate Cancer | Recruiting | Santa Chiara Hospital | 3000 | 2016-12-16 | 2024-06-25 | |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label - Hormone Sensitive Prostate Cancer, Prostate Cancer | Phase 3 | Active not recruiting | Pfizer | 1068 | 2014-12-17 | 2026-10-26 |
Prostatic Neoplasms (13) · Neoplasm Metastasis (3) · Cardiovascular Diseases (1) · Genital Neoplasms, Male (1) · Urogenital Neoplasms (1)
Genital Diseases (13) · Genital Diseases, Male (13) · Male Urogenital Diseases (13) · Neoplasms (13) · Neoplasms by Site (13) · Prostatic Diseases (13) · Urogenital Diseases (13) · Genital Neoplasms, Male (12) · Urogenital Neoplasms (12) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
enzalutamide (4) · Androgen Antagonists (3) · Docetaxel (3) · darolutamide (3) · Abiraterone Acetate (2) · Leuprolide (2) · Radiotherapy (2) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (2) · Gonadotropin-Releasing Hormone (1) · Goserelin (1) · Metastasectomy (1) · Nivolumab (1) · PF06821497 (1) · Positron Emission Tomography Computed Tomography (1) · Radiosurgery (1)
Pfizer (2) · Alliance Foundation Trials, LLC. (1) · Atish Choudhury, MD (1) · Brigham and Women's Hospital (1) · Eli Lilly and Company (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · National University Hospital, Singapore (1) · Rabin Medical Center (1) · RenJi Hospital (1) · Santa Chiara Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Universitaire Ziekenhuizen KU Leuven (1) · University of Miami (1) · Xiao X. Wei, MD (1)
United States (7) · Canada (3) · China (3) · Italy (3) · Australia (2) · Belgium (2) · Brazil (2) · Finland (2) · France (2) · Israel (2) · Netherlands (2) · Poland (2) · Slovakia (2) · South Korea (2) · Spain (2)
Atish Choudhury, MD, PhD (1) · Benjamin J Rich, MD (1) · David Margel, MD, PhD (1) · Edmund Chiong, MBBS, PhD (1) · Evanthia Galanis, MD (1) · Heather Jacene, MD (1) · Lixxin Hua (1) · Xiao X Wei, MD (1)
PMID 34350976, PMID 34385241, PMID 36503429, PMID 37119051, PMID 37851874, PMID 38320501, PMID 38421243, PMID 38421252, PMID 40140551, PMID 41124201, PMID 41349040, PMID 41364813, PMID 42333826